AbbVie (ABBV) announced that it has submitted a New Drug Application to the U.S. FDA for tavapadon, a novel selective dopamine D1/D5 receptor partial agonist that was studied as a once daily oral treatment for Parkinson’s disease.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie’s Promising Phase 1 Study on ABBV-CLS-579: A Potential Game-Changer in Cancer Treatment
- Genmab upgraded to Buy at Guggenheim on royalty revenue upside potential
- Kroger, Merck, Workday, AbbVie, Eli Lilly: Trending by Analysts
- AbbVie’s Promising Study on GUB014295: A Potential Breakthrough in Weight Management
- AbbVie’s Phase 3 Pediatric Constipation Study Completes, Potential Market Impact Looms